



# Combined targeted therapy using APR-246 for the treatment of pediatric TP53 mutant acute lymphoblastic leukemia

## Monotherapy



## Combination therapy



TP53mut BCP-ALL

In combination therapy, APR-246 strongly synergized with the genotoxic agent doxorubicin leading to superior leukemia-free survival in vivo